Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.51)
# 285
Out of 5,139 analysts
123
Total ratings
51.79%
Success rate
25.55%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Reiterates: Buy | $44 | $27.02 | +62.84% | 6 | Feb 10, 2026 | |
| KOD Kodiak Sciences | Reiterates: Buy | $38 | $26.67 | +42.51% | 9 | Feb 10, 2026 | |
| IMUX Immunic | Reiterates: Buy | $8 | $0.97 | +720.77% | 7 | Feb 9, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.18 | +408.47% | 4 | Feb 6, 2026 | |
| FBLG FibroBiologics | Reiterates: Buy | $5 | $0.25 | +1,890.45% | 8 | Jan 2, 2026 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $28.06 | +99.57% | 13 | Nov 12, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $11.96 | +117.38% | 11 | Oct 31, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $65.54 | +34.27% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $8.50 | +41.18% | 7 | Aug 15, 2025 | |
| LYRA Lyra Therapeutics | Reiterates: Neutral | $16 | $1.49 | +973.83% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $12.05 | +364.73% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.57 | +124.09% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $6.74 | +48.37% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.08 | +96.85% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $26.93 | +18.83% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $9.17 | +292.58% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $513.83 | -94.55% | 1 | Aug 22, 2023 |
Zenas BioPharma
Feb 10, 2026
Reiterates: Buy
Price Target: $44
Current: $27.02
Upside: +62.84%
Kodiak Sciences
Feb 10, 2026
Reiterates: Buy
Price Target: $38
Current: $26.67
Upside: +42.51%
Immunic
Feb 9, 2026
Reiterates: Buy
Price Target: $8
Current: $0.97
Upside: +720.77%
Akebia Therapeutics
Feb 6, 2026
Reiterates: Buy
Price Target: $6
Current: $1.18
Upside: +408.47%
FibroBiologics
Jan 2, 2026
Reiterates: Buy
Price Target: $5
Current: $0.25
Upside: +1,890.45%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $28.06
Upside: +99.57%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $11.96
Upside: +117.38%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $65.54
Upside: +34.27%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $8.50
Upside: +41.18%
Lyra Therapeutics
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $1.49
Upside: +973.83%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $12.05
Upside: +364.73%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $3.57
Upside: +124.09%
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $6.74
Upside: +48.37%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.08
Upside: +96.85%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $26.93
Upside: +18.83%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $9.17
Upside: +292.58%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $513.83
Upside: -94.55%